[1] Expert Committee of Chinese Guidelines for Prevention and Treatment of Thrombotic Diseases. Chinese Guidelines for Prevention and Treatment of Thrombotic Diseases[J]. Chinese Medical Journal(中华医学杂志), 2018,98(36): 2861-2888. [2] Institute for Safe Medication Practices. High-alert medications in acute care settings[EB/OL]. (2014-07-25)[2018-01-27]. http://www.ismp.org/recommendations/high-alert-medications-acute-list. [3] Professional Committee of Hospital Pharmacy of Chinese Pharmaceutical Association. Recommended Catalogue of High-Alert Drugs in China (2019)[EB/OL].(2019-05-27)[2020-09-08].http://www.psmchina.cn/psm/specialtopic/jsyp/jsyp.html. [4] MOORE T, COHEN M, FURBERG C. Quarter W (2016) Quarter 4. 2017[EB/OL].(2017-07-12)[2020-09-08].https://www.ismp.org/sites/default/files/attachments/2018-01/2016Q4_1.pdf. [5] PIAZZA G, NGUYEN TN, CIOS D, et al.Anticoagulation-associated adverse drug events[J]. Am J Med, 2011, 124(12): 1136-1142. [6] VIPREY M, JEANNIN R, PIRIOU V, et al.Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicenter, cross-sectional study[J]. J Clin Pharm Ther, 2017, 42(1): 58-63. [7] Expert consensus on management of medication errors in China[J]. Journal of Adverse Drug Reactions(药物不良反应杂志), 2014(6): 321-326. [8] LI XL, YAN SY, WANG YQ, et al.Analysis of 1165 medication errors in 22 hospitals in Beijing[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2013, 15(2): 64-68. [9] WANG C.Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism[J]. Chinese Medical Journal(中华医学杂志), 2018, 98(14): 1060-1087. [10] STEFFEL J, VERHAMME P, POTPARA TS, et al.The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Eur Heart J, 2018, 39(16): 1330-1393. [11] Chinese Expert Consensus on Antithrombotic Management of Patients with Coronary Heart Disease and Atrial Fibrillation[J]. Chinese Journal of Cardiovascular Diseases(中华心血管病志), 2020, 48(7): 552-564. [12] CONNOLLY SJ, EZEKOWITZ MD, YUSUF S,et a1.Dabigatran versus warfarin in patients with atrial fibrillation[J].N Engl J Med, 2009, 361(12):1139-1151. [13] STEFFEL J, COLLINS R, ANTZ M, et al.2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace, 2021,23(10):1685. [14] GOV.UK. Rivaroxaban (Xarelto▼): reminder that 15 mg and 20 mg tablets should be taken with food[EB/OL].(2019-07-17) [2020-09-08]. https://www.gov.uk/drug-safety-update/rivaroxaban-xarelto-reminder-that-15-mg-and-20-mg-tablets-should-be-taken-with-food. [15] PIRAN S, SCHULMAN S, PANJU M, et al.Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers[J]. J Thromb Thrombolysis, 2018, 45(1): 180-185. |